PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
Africa
HIV
adherence
persistence
pre-exposure prophylaxis
young women
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
14
09
2021
accepted:
23
06
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
16
7
2022
Statut:
ppublish
Résumé
HIV incidence remains high among African adolescent girls and young women (AGYW). The primary objective of this study is to assess pre-exposure prophylaxis (PrEP) initiation, use, persistence and HIV acquisition among African AGYW offered PrEP in order to inform PrEP scale-up. POWER was a prospective implementation science evaluation of PrEP delivery for sexually active HIV-negative AGYW ages 16-25 in family planning clinics in Kisumu, Kenya and youth and primary healthcare clinics in Cape Town and Johannesburg, South Africa. Follow-up visits occurred at month 1 and quarterly for up to 36 months. PrEP users were defined based on the month 1 refill. PrEP persistence through month 6 was assessed using Kaplan-Meier survival analysis among AGYW with a month 1 visit, defining non-persistence as an ≥15 day gap in PrEP availability for daily dosing. PrEP execution was evaluated in a subset with PrEP supply from the prior visit sufficient for daily dosing by measuring blood tenofovir diphosphate (TFV-DP) levels. From June 2017 to September 2020, 2550 AGYW were enrolled (1000 in Kisumu, 787 in Cape Town and 763 in Johannesburg). Median age was 21 years, 66% had a sexual partner of unknown HIV status, and 29% had chlamydia and 10% gonorrhoea. Overall, 2397 (94%) initiated PrEP and 749 (31%) had a refill at 1 month. Of AGYW who could reach 6 months of post-PrEP initiation follow-up, 128/646 (20%) persisted with PrEP for 6 months and an additional 92/646 (14%) had a gap and restarted PrEP. TFV-DP levels indicated that 47% (91/193) took an average of ≥4 doses/week. Sixteen HIV seroconversions were observed (incidence 2.2 per 100 person-years, 95% CI 1.2, 3.5); 13 (81%) seroconverters either did not have PrEP dispensed in the study interval prior to seroconversion or TFV-DP levels indicated <4 doses/week in the prior 6 weeks. In this study of PrEP integration with primary care and reproductive health services for African AGYW, demand for PrEP was high. Although PrEP use decreased in the first months, an important fraction used PrEP through 6 months. Strategies are needed to simplify PrEP delivery, support adherence and offer long-acting PrEP options to improve persistence and HIV protection.
Identifiants
pubmed: 35822945
doi: 10.1002/jia2.25962
pmc: PMC9278271
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT03490058']
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25962Subventions
Organisme : NIMH NIH HHS
ID : P30 MH062246
Pays : United States
Investigateurs
Josephine Odoyo
(J)
Hilda Machafu
(H)
Mary-Josephine Osore
(MJ)
Ethel Osome
(E)
Fredrick Omondi
(F)
Ben Kwach
(B)
David Ang'awa
(D)
Bernard Nyerere
(B)
Merceline Awuor
(M)
Annabel Dola
(A)
John Bosco Tsetso
(JB)
Sherine Odek
(S)
Sylvia Mugalla
(S)
Vincent Momanyi
(V)
Peris Otieno
(P)
Brenda Misiko
(B)
Joel Odondi
(J)
Calvin Obuya
(C)
Boblief Otieno
(B)
Eric Seda
(E)
Alfred Obiero
(A)
Rachel Mwakisha
(R)
Petronilla Njenga
(P)
Dorothy Zakariya
(D)
Lindile Nonjinge
(L)
Robin Julies
(R)
Pamela Fuzile
(P)
Thando Xeketwana
(T)
Lwazi Thami
(L)
Nkosiyabo Futshane
(N)
Desmond Raqa
(D)
Nomvuyiseko Mkatshana
(N)
Yolanda Mpanda
(Y)
Thapelo Tlou
(T)
Kefilwe Kgabo
(K)
Samukelo Mbele
(S)
Phumzile Nyamane
(P)
Lerato Lunika
(L)
Sanele Gumede
(S)
Melt Ndlovu
(M)
Nomhle Khoza
(N)
Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
BMC Health Serv Res. 2019 Mar 28;19(1):195
pubmed: 30922372
AIDS Res Ther. 2020 Sep 7;17(1):55
pubmed: 32894138
Lancet HIV. 2017 Sep;4(9):e402-e410
pubmed: 28747274
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298
pubmed: 31328444
JAMA Netw Open. 2019 Dec 2;2(12):e1917134
pubmed: 31825501
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608
pubmed: 27846073
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Lancet. 2019 Jul 27;394(10195):303-313
pubmed: 31204114
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Acquir Immune Defic Syndr. 2010 Apr;53(5):606-13
pubmed: 19838129
BMC Health Serv Res. 2021 Aug 28;21(1):888
pubmed: 34454505
Sex Health. 2018 Nov;15(6):578-586
pubmed: 30408432
J Int AIDS Soc. 2021 Jul;24 Suppl 4:e25755
pubmed: 34288453
AIDS Behav. 2021 Jul;25(7):2046-2053
pubmed: 33389323
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8
pubmed: 24784763
Gates Open Res. 2021 Jul 27;5:113
pubmed: 34988373
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
N Engl J Med. 2016 Dec;375(22):2121-2132
pubmed: 26900902
Reprod Health Matters. 2006 May;14(27):109-18
pubmed: 16713885
JAMA. 2018 Mar 27;319(12):1261-1268
pubmed: 29584848
PLoS Med. 2021 Jun 18;18(6):e1003670
pubmed: 34143779
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
J Int AIDS Soc. 2020 Nov;23(11):e25636
pubmed: 33247553
Front Reprod Health. 2021 Jun;3:
pubmed: 34318291
Curr HIV/AIDS Rep. 2013 Mar;10(1):89-102
pubmed: 23184582
PLoS One. 2021 Oct 14;16(10):e0258542
pubmed: 34648589
AIDS Behav. 2021 Jul;25(7):2154-2165
pubmed: 33521908
South Afr J HIV Med. 2016 Mar 15;17(1):455
pubmed: 29568613
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):323-330
pubmed: 32539288
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):363-5
pubmed: 23187946